[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tranexamic-acid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tranexamic-acid":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,71,102,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100566649","phase-2-preoperative-tranexamic-acid-txa-to-prevent-bleeding-in-patients-undergoing-major-colorectal-surgery-100566649",false,"NCT06657924","Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery","Inclusion Criteria:\n\n1. Adults 18 years or older\n2. Undergoing elective or non-elective inpatient abdominal and pelvic colorectal surgery\n\nExclusion Criteria:\n\n1. Creatinine clearance less than 30 mL\u002Fminute\n2. Long-term dialysis\n3. Known defective color vision (color blind)\n4. Pregnancy\n5. History of venous or arterial thromboembolism, or active thromboembolic disease\n6. Disseminated intravascular coagulation (DIC) - clinically suspected and\u002For confirmed by platelet count on CBC, fibrinogen, INR and PTT.","ALL","18 Years","100 Years",{"count":19,"type":20},394,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this prospective pragmatic randomized clinical trial is to determine if preoperative administration of tranexamic acid (TXA) reduces bleeding during and after major colorectal surgery. The primary questions are:\n\n* Does TXA reduce bleeding during and after surgery (change in hemoglobin from before surgery to lowest value after surgery within 30 days)\n* Does TXA reduce bleeding complications within 30 days of surgery (blood transfusion, return to the operating room or procedural intervention for bleeding, death due to bleeding)\n* Does TXA increase the risk of thromboembolic complications within 30 days of surgery (cerebrovascular accident, myocardial infarction, deep venous thrombosis, pulmonary embolism)\n\nResearchers will compare preoperative TXA to no TXA to answer the above questions.\n\nParticipants who receive TXA will receive 1 g TXA IV at the beginning and end of surgery in the operating room.",[26,27,28,29],"Bleeding","Colorectal Disorders","Thromboembolism","Tranexamic Acid",[29,31,26,32,28],"TXA","Colorectal Surgery","RECRUITING","2026-05-27",{"date":36,"type":37},"2026-05-28","ACTUAL",{"date":39,"type":37},"2025-02-11",{"date":41,"type":20},"2027-10-01",{"name":43,"class":44},"Kristen Ban","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100567238","phase-2-effect-of-txa-on-reducing-bruising-after-filler-injection-100567238","NCT06665594","Effect of TXA on Reducing Bruising After Filler Injection","Does TXA Reduce Bruising After Hyaluronic Acid Filler Injection? A Prospective Half Face Study","Inclusion Criteria:\n\n* Age equal to or greater than 18 but less than or equal to 89 years.\n* Participants interested in facial filler (HA) injection.\n* English speaking.\n\nExclusion Criteria:\n\n* Minors or under the age of 18\n* Participant over the age of 89\n* Pregnant or breast-feeding women\n* Individuals unable to give consent due to another condition such as impaired decision-making capacity.\n* Individuals with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis\n* Participants undergoing unilateral facial filler (HA) injection\n* Participants with history of hypersensitivity to TXA or any of the other ingredients\n* Participants that are on current therapeutic anticoagulation therapy and aspirin use\n* Participants with stage 2 or greater renal failure\n* Participants on hemodialysis or peritoneal dialysis\n* History of diabetes or seizures\n* Current tobacco smokers\n* Acquired defective color vision",true,"89 Years",{"count":56,"type":20},40,[23],"The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is:\n\n* Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after HA injection?\n\nParticipants will receive the study medication along with the standard facial filler injection and complete surveys.",[60,61,29],"Facial Filler Injections","Hyaluronic Acid","2026-05-19",{"date":64,"type":37},"2026-05-20",{"date":66,"type":37},"2025-12-05",{"date":68,"type":20},"2026-11",{"name":70,"class":44},"University of Wisconsin, Madison",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":78,"minAge":16,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100633694","clinical-efficacy-and-mechanisms-of-a-topical-azone-tranexamic-acid-aloe-polysaccharide-gel-in-the-treatment-of-melasma-100633694","NCT07530016","Clinical Efficacy and Mechanisms of a Topical Azone-Tranexamic Acid-Aloe Polysaccharide Gel in the Treatment of Melasma","Melasma is a Common Pigmented Skin Disease, Related to Genetics and Ultraviolet Rays, and Prone to Causing Psychological Problems. The Current Treatments Have Limitations. The Combination Gel of Tranexamic Acid, Aloe Polysaccharide and Lauric Azonide is Expected to Enhance Efficacy and Reduce Side Effects. This Study Explores Its Therapeutic Effect and Mechanism, Providing New Strategies.","Inclusion Criteria:\n\nAdult patients aged 18-50 years diagnosed with melasma Famale\n\nExclusion Criteria:\n\n* Patients with contraindications to melatonin, including pregnancy, breastfeeding, autoimmune disorders, bleeding disorders, and diabetes, or contraindications to tranexamic acid, including thromboembolic events, history of thrombosis, renal impairment, and pregnancy or breastfeeding.\n\nPatients with a history of hypersensitivity to any of the medications. Patients already taking treatment of melasma","FEMALE","50 Years",{"count":81,"type":20},10,[83],"NA","Melasma is a common pigmentation disorder among young and middle-aged women, characterized by symmetrical brown-black patches on the face. It is related to genetics, ultraviolet radiation, endocrine factors and inflammation, and can lead to psychological problems and affect quality of life. Current treatments such as hydroquinone stimulation, laser therapy, and oral tranexamic acid have a high recurrence rate and poor compliance. The new gel formulation, which combines tranexamic acid (to inhibit tyrosinase), aloe polysaccharides (anti-inflammatory and repair), and lauric azon (promotes penetration), is expected to enhance efficacy and reduce side effects. This study aims to explore its clinical efficacy and synergistic mechanism, providing new strategies for the treatment of Melasma.",[86,87,29,88],"Melasma","Treatment of Stable Melasma","Laurocapram",[90,91],"Improve transdermal efficiency","Treatment of stable melasma","NOT_YET_RECRUITING","2026-04-08",{"date":95,"type":37},"2026-04-14",{"date":97,"type":20},"2026-08-12",{"date":99,"type":20},"2028-11-16",{"name":101,"class":44},"The First Affiliated Hospital of Xinxiang Medical College",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":45},"100605062","efficacy-and-safety-of-tranexamic-acid-in-adult-liver-transplantation---esta-trial-100605062","NCT07157631","Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial","A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation (ESTA Trial)","ESTA","Inclusion Criteria:consenting adults aged at least 18 years who are scheduled for allogeneic liver transplantation with general anesthesia.\n\n\\-\n\nExclusion Criteria:1) History of arterial or venous thrombosis within 3 months; 2) Re-transplantation; 3) Known allergy to tranexamic acid; 4) Participation in potentially conflicting clinical trials; 5) Considered by the responsible surgeon or anesthesiologist to be unsuitable.\n\n\\-",{"count":111,"type":20},1546,[83],"We propose a multi-center randomized trial to test the primary hypothesis that tranexamic acid is superior to placebo on blood loss in adult orthotopic liver transplantation within the initial 24 hours and that tranexamic acid is non-inferior to placebo for a composite of thrombotic events within the initial 7 postoperative days. Secondarily, we will determine whether tranexamic acid is superior to placebo on total postoperative drainage volume and blood product transfusion within the initial 3 postoperative days.\n\nWe propose to randomize patients to 2.0 g of tranexamic acid intravenously at the start of surgery or a comparable volume of 0.9% normal saline placebo. Because demonstrating safety will require more patients, our sample size is based on safety. Randomizing 1546 patients will provide 80% power for detecting a non-inferiority margin of 4% with a baseline incidence of 10% for composite thrombotic events within the initial 7 postoperative days.",[115,29,116],"Liver Transplantation","End-stage Liver Disease (ESLD)",[115,118],"tranexamic acid","2025-12-02",{"date":121,"type":37},"2025-12-08",{"date":123,"type":37},"2025-11-01",{"date":125,"type":20},"2027-12-01",{"name":127,"class":44},"RenJi Hospital",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":78,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":45},"100516886","phase-3-comparing-intramyometrial-tranexamic-acid-and-oxytocin-for-blood-loss-in-cesarean-section-100516886","NCT06010368","Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section","The Effect of Intramyometrial Tranexamic Acid Versus Intramyometrial Oxytocin in Reducing Blood Loss During and After Elective Cesarean Section in Term Primigravida: A Double-blinded, Randomized, Comparative-placebo Trial","nclusion Criteria:\n\n* Women booked for a primary elective cesarean section, not in active labor\n* Aged between 20-40 years.\n* BMI 18.5-29.9 kg\u002F m2 pre-pregnancy weight\n* Term pregnancies (Early term: between 37 weeks, 0 days and 38 weeks, 6 days. Full term: between 39 weeks, 0 days and 40 weeks, 6 days. Late term: between 41 weeks, 0 days and 41 weeks, 6 days).\n* Singleton pregnancies.\n* Indication of elective cesarean section (Malpresentation, Malposition, Cephalopelvic disproportion, active herpes)\n* Fetal macrosomia (Macrosomia is defined as birth-weight over 4,000 g irrespective of gestational age)\n* Certain congenital fetal malformation and skeletal disorders (Several congenital anomalies are controversial indications for cesarean delivery; these include fetal neural tube defects (to avoid sac rupture), particularly defects that are larger than 5-6 cm in diameter as anterior cystic hygroma vascular sacrococcygeal teratoma, giant omphalocele and hydrocephalus with an enlarged biparietal diameter, and some skeletal dysplasia such as type III osteogenesis imperfecta. (Hamrick et al., 2008)\n\nExclusion Criteria:\n\n* Placenta previa.\n* Maternal hypertension and Preeclampsia.\n* Diabetes mellitus.\n* Severe medical disorder (renal or hepatic).\n* Multiple Fibroid uterus.\n* Multiple pregnancies.\n* Polyhydramnios.\n* Previous uterine surgery as myomectomy.\n* Contraindication to spinal anesthesia.\n* Blood coagulopathy and bleeding disorder.\n* Marked maternal anemia (Preoperative hemoglobin \\\u003C9 gm\u002Fdl).\n* Contraindications to TXA or oxytocin therapy (e.g. allergy)","20 Years","40 Years",{"count":138,"type":20},150,[140],"PHASE3","Cesarean section is the most prevalent operation among women globally, 10-15% (1, 2). Recent research has shown Egypt to be the third-largest country globally, with an estimated 52% cesarean sections (3). However, the cesarean section has many serious complications, including the primary postpartum hemorrhage (PPH) (4). During labor, the average blood loss is about 300 to 400 ml. Bleeding postpartum is known as losing over five hundred milliliter of blood following a vaginal birth and losing over one thousand milliliter after the cesarean section (5). The prime cause of maternal death rate is postpartum bleeding, predominately in poor countries, and the estimated mortality number due to postpartum bleeding is one hundred thousand per year (6). Therefore, it is essential to reduce bleeding during and after CS to diminish maternal mortality and morbidity (7). The most successful technique for decreasing PPH is the active third stage labor management, requiring prophylactic uterotonic drugs like oxytocin, ergometrine malate, prostaglandins (E1, E2, and F2α), and combinations of them, or hemostatic agent as tranexamic acid (Kapron) and Etamsylate (Dicynon) (8, 9).",[143,29,144,145],"Cesarean Section Complications","Oxytocin","Post Partum Hemorrhage","2024-09-02",{"date":148,"type":37},"2024-09-05",{"date":150,"type":20},"2024-10-01",{"date":152,"type":20},"2026-01-01",{"name":154,"class":44},"Cairo University"]